01 Lecture - MI260: Bayesian MBMA to Support Decision Making in Drug Development (2013)
Canakinumab is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.